COVID-19 trials registries data warehouse

http://en.irct.ir/trial/48517

hasan adeli

adeli@muq.ac.ir

2020-05-31

Completed

RCT

Randomized

Parallel

Open label

single-center

Treatment

Laboratory confirmation of Covid19 infection with reverse transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source A new organ dysfunction related to Covid19 Being an adult

Intention to commit suicide (interfering with interferon (IFN) -b1b). Sensitivity or sensitivity reaction to Lupinavir / Ritonavir or IFN-β1b recombinant, including toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome. ALT above 5 times normal Use of drugs that are contraindicated with lopinavir / ritonavir and should not be substituted or discontinued during the study period, such as CYP3A inhibitors. pregnancy.Eligible female participants are tested at gestational age before enrolling in the study for pregnancy. HIV Vulnerable groups

2

Ghoum University of Medical Sciences

18

70

Iran

Severe/critical disease at enrollment

7: Severe/critical disease at enrollment

60

death within 30 days of hospitalization

Phase 3

[{"arm_notes": "", "treatment_id": 663, "treatment_name": "Interferon", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]